Table 3 Potential improvement in adequacy of empiric coverage for patients with critical care infections at 12, 24, and 48 hours using WISCA empiric regimens
WISCA empiric regimens | Percentage of VAP or CRBSI with documented adequate coverage by this regimen (n = 163) | Excess percentage of adequate coverage compared to retrospective cohort | ||
|---|---|---|---|---|
12 h | 24 h | 48 h | ||
Monotherapy | ||||
Ciprofloxacin | 110 (67%) | +30% | +16% | -8% |
Tobramycin | 75 (46%) | +9% | -5% | -29% |
Ceftriaxone | 77 (47%) | +10% | -4% | -28% |
Ceftazidime | 77 (47%) | +10% | -4% | -28% |
Pip.-Tazo. | 103 (63%) | +26% | +12% | -12% |
Ertapenem | 93 (57%) | +20% | +6% | -18% |
Meropenem | 121 (74%) | +37% | +23% | -3% |
Cloxacillin | 30 (18%) | -19% | -33% | -57% |
Vancomycin | 67 (41%) | +5% | -10% | -34% |
Linezolid | 68 (42%) | +6% | -9% | -33% |
Dual combination therapy | ||||
Meropenem + Vancomycin | 152 (93%) | +56% | +42% | +18% |
Ertapenem + Vancomycin | 127 (78%) | +41% | +27% | +3% |
Pip.-Tazo. + Vancomycin | 144 (88%) | +51% | +37% | +13% |
Ceftazidime + Vancomycin | 141 (87%) | +50% | +36% | +12% |
Ceftriaxone + Vancomycin | 117 (72%) | +35% | +21% | -3% |
Ciprofloxacin + Vancomycin | 151 (93%) | +56% | +42% | +18% |
Tobramycin + Vancomycin | 151 (93%) | +56% | +42% | +18% |
Ciprofloxacin + Cloxacillin | 134 (82%) | +45% | +31% | +7% |
Tobramycin + Cloxacillin | 116 (71%) | +34% | +20% | -4% |
Meropenem + Tobramycin | 126 (77%) | +40% | +26% | +2% |
Ertapenem + Tobramycin | 126 (77%) | +40% | +26% | +2% |
Pip.-Tazo. + Tobramycin | 128 (79%) | +42% | +28% | +4% |
Ceftazidime + Tobramycin | 102 (63%) | +26% | +12% | -12% |
Ceftriaxone + Tobramycin | 115 (71%) | +34% | +20% | -4% |
Meropenem + Ciprofloxacin | 143 (88%) | +51% | +37% | +13% |
Ertapenem + Ciprofloxacin | 143 (88%) | +51% | +37% | +13% |
Pip.-Tazo. + Ciprofloxacin | 144 (88%) | +51% | +37% | +13% |
Ceftazidime + Ciprofloxacin | 137 (84%) | +47% | +33% | +9% |
Ceftriaxone + Ciprofloxacin | 136 (83%) | +46% | +32% | +8% |
Ciprofloxacin + Tobramycin | 135 (82%) | +45% | +31% | +7% |